Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 9/20 | 0.58 |
| ▸ | HTT | P42858 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2701506 | 0.82 | LMNA (1.00) | LMNAMAPTHTTSMN1; SMN2NPC1 | |
| SCHEMBL164314 | 0.80 | LMNA (0.61) | LMNAMAPTHTTSMN1; SMN2NPC1 | |
| SCHEMBL1514147 | 0.80 | LMNA (0.61) | LMNAMAPTHTTSMN1; SMN2NPC1 | |
| SCHEMBL1158327 | 0.80 | LMNA (0.61) | LMNAMAPTHTTSMN1; SMN2NPC1 | |
| SCHEMBL30688636 | 0.80 | LMNA (0.47) | LMNAMAPTHTTSMN1; SMN2NPC1 | |
| SCHEMBL20489517 | 0.79 | MAPT (0.58) | LMNAMAPTHTTSMN1; SMN2NPC1 | |
| SCHEMBL1192351 | 0.79 | LMNA (0.46) | LMNAMAPTHTTSMN1; SMN2NPC1 | |
| SCHEMBL21206730 | 0.79 | LMNA (0.60) | LMNAMAPTHTTSMN1; SMN2NPC1 | |
| SCHEMBL2501465 | 0.78 | LMNA (0.44) | LMNAMAPTHTTSMN1; SMN2NPC1 | |
| SCHEMBL13480831 | 0.77 | LMNA (0.57) | LMNAMAPTHTTSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366612-A1 | COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC. | 2024-11-07 | — | — | US | disclosed |
| US-20240294524-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2024-09-05 | — | — | US | disclosed |
| EP-4416156-A1 | COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING | Remix Therapeutics Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| CN-118047791-A | URAT1 inhibitor containing aminopyridine structure, and preparation method and application thereof | 山东省药学科学院 | 2024-05-17 | — | — | CN | disclosed |
| CN-117343081-A | MAT2A inhibitor, pharmaceutical composition and application thereof | 南京正大天晴制药有限公司 | 2024-01-05 | — | — | CN | disclosed |
| EP-3466929-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | MILLENNIUM PHARM INC (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-3466929-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | MILLENNIUM PHARM INC (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2023064879-A1 | COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| US-20230113598-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | BIOGEN IDEC MA INC. | 2023-04-13 | — | — | US | disclosed |
| US-20210070752-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | VIRACTA THERAPEUTICS, INC. | 2021-03-11 | — | — | US | disclosed |
| WO-2006096338-A1 | 1,3-THIAZOLE-5-CARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE AG (DE) | 2006-09-14 | — | — | WO | disclosed |
| EP-1687306-A1 | BICYCLIC PYRIMIDIN-4-(3H)-ONES AND ANALOGUES AND DERIVATIVES THEREOF WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) | MERCK SHARP & DOHME LTD. (GB) | 2006-08-09 | — | — | EP | disclosed |
| EP-1560827-A1 | ANTI-INFECTIVE AGENTS | Abbott Laboratories (US) | 2005-08-10 | — | — | EP | disclosed |
| WO-2005049613-A1 | BICYCLIC PYRIMIDIN-4-(3H)-ONES AND ANALOGUES AND DERIVATIVES THEREOF WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) | MERCK SHARP & DOHME LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
| US-20050075331-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2005-04-07 | — | — | US | disclosed |
| US-20040167123-A1 | Anti-infective agents | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040162285-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2004-08-19 | — | — | US | disclosed |
| WO-2004041818-A1 | ANTI-INFECTIVE AGENTS | ABBOTT LABORATORIES (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040097492-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2004-05-20 | — | — | US | disclosed |
| US-20040087577-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097492-A1 | Anti-infective agents | POLR1C, RPL5, POLB | LMNA 3232/4885MAPT 4106/4885HTT 4085/4885 |
| US-20240294524-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | LMNA 3553/4885MAPT 3529/4885HTT 2830/4885 |
| US-20240366612-A1 | COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING | SNRPA, NSUN2, SNRPA1 | LMNA 227/4885MAPT 3442/4885HTT 838/4885 |
| US-20040162285-A1 | Anti-infective agents | POLR1C, RPL5, POLB | LMNA 3232/4885MAPT 4106/4885HTT 4085/4885 |
| US-20040167123-A1 | Anti-infective agents | SERPINB1, CYP51A1, ZC3HAV1 | LMNA 4000/4885MAPT 4529/4885HTT 4340/4885 |
| US-20210070752-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | LMNA 3553/4885MAPT 3529/4885HTT 2830/4885 |
| US-20050075331-A1 | Anti-infective agents | RPL35, POLI, POLRMT | LMNA 4225/4885MAPT 4234/4885HTT 3990/4885 |
| US-20040087577-A1 | Anti-infective agents | POLR1C, RPL5, POLB | LMNA 3232/4885MAPT 4106/4885HTT 4085/4885 |
| US-20230113598-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | LMNA 3553/4885MAPT 3529/4885HTT 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.